ForeSENTIA TESTS FOR:
Genetic alterations include Single Nucleotide Variants (SNVs), Insertions & Deletions (INDELs), Copy Number Alterations (CNAs) and Rearrangements.
They can drive tumor development in multiple types of cancer, and can be responsible for therapy resistance and cancer relapse.
Gene Targeted Therapies
MSI is caused by defects in the DNA mismatch repair mechanisms, resulting in the accumulation of short repeated DNA sequences known as microsatellites, which cause genetic hypermutability.
MSI can offer prognostic and therapeutic value for patients with different types of solid tumors, including but not limited to: colorectal, endometrial, gastric, prostate and bladder cancer.
TMB indicates the total number of somatic mutations found in a tumor per megabase.
Pan-Cancer Plus provides > 1Mb of genomic coverage for accurate TMB scoring. Evidence suggests that TMB can offer prognostic value for patients with solid tumors, including rare types, as well as therapeutic opportunities for TMB-high patients in a tumor-agnostic manner
Both MSI and TMB are genomic biomarkers that identify patients eligible for immunotherapy treatment. Although some correlation exists between the two, MSI and TMB scores are not always associated. Results for each biomarker depend on the tumor type and the underlying mechanisms and pathways involved.
Pan-Cancer Plus can assess both genomic biomarkers and provide an informative interpretation of the results, indicating the applicable approved therapies and clinical trials related to immunotherapy.